Ironwood Investment Counsel LLC Purchases 1,877 Shares of Elevance Health, Inc. $ELV

Ironwood Investment Counsel LLC raised its position in shares of Elevance Health, Inc. (NYSE:ELV) by 23.8% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 9,768 shares of the company’s stock after acquiring an additional 1,877 shares during the quarter. Ironwood Investment Counsel LLC’s holdings in Elevance Health were worth $3,424,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the company. Blume Capital Management Inc. boosted its position in Elevance Health by 0.7% during the 4th quarter. Blume Capital Management Inc. now owns 6,185 shares of the company’s stock valued at $2,168,000 after acquiring an additional 40 shares in the last quarter. TD Private Client Wealth LLC boosted its position in shares of Elevance Health by 30.3% in the 4th quarter. TD Private Client Wealth LLC now owns 3,979 shares of the company’s stock worth $1,395,000 after purchasing an additional 926 shares in the last quarter. North Dakota State Investment Board bought a new stake in shares of Elevance Health in the 4th quarter worth approximately $2,719,000. Elyxium Wealth LLC bought a new stake in shares of Elevance Health in the 4th quarter worth approximately $58,000. Finally, Leuthold Group LLC bought a new stake in shares of Elevance Health in the 4th quarter worth approximately $7,898,000. 89.24% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently commented on ELV. Leerink Partners set a $364.00 price target on Elevance Health in a research report on Thursday, April 23rd. Mizuho dropped their price target on Elevance Health from $413.00 to $350.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 11th. Guggenheim boosted their price target on Elevance Health from $396.00 to $399.00 and gave the stock a “buy” rating in a research report on Friday, April 24th. Weiss Ratings raised Elevance Health from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, April 24th. Finally, UBS Group set a $400.00 price target on Elevance Health in a research report on Thursday, January 29th. Thirteen analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $384.58.

Elevance Health Price Performance

Shares of NYSE ELV opened at $392.74 on Monday. Elevance Health, Inc. has a twelve month low of $273.71 and a twelve month high of $412.96. The firm has a market cap of $85.29 billion, a P/E ratio of 16.71, a PEG ratio of 2.23 and a beta of 0.66. The company has a 50 day moving average of $322.88 and a 200 day moving average of $333.97. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.70.

Elevance Health (NYSE:ELV) last announced its quarterly earnings data on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, topping analysts’ consensus estimates of $10.74 by $1.84. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The company had revenue of $49.49 billion during the quarter, compared to analyst estimates of $48.21 billion. During the same period in the previous year, the business earned $11.97 EPS. The firm’s revenue for the quarter was up 1.5% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 19.850- EPS. As a group, research analysts expect that Elevance Health, Inc. will post 26.79 EPS for the current fiscal year.

Elevance Health Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 25th. Investors of record on Wednesday, June 10th will be issued a $1.72 dividend. This represents a $6.88 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date is Wednesday, June 10th. Elevance Health’s payout ratio is presently 29.26%.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.